# LTR Pharma Launches Roxus ED Nasal Spray in the U.S.

- URL: https://stocks.freetheai.org/news/ltr-pharma-launches-roxus-ed-nasal-spray-in-the-u-s-ede5eb
- Published: 2026-10-15T09:00:00Z
- Category: company_news; sentiment: mixed; impact: medium
- Symbols: [ASX:LTP](https://stocks.freetheai.org/symbols/ASX-LTP)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

LTR Pharma Limited (ASX:LTP) has introduced Roxus, a prescription nasal spray treating erectile dysfunction, into the U.S. market. The product uses intranasal vardenafil and is being distributed through telemedicine partner Mavrox. LTR Pharma stated that prior studies on its underlying SPONTAN formulation demonstrated median peak blood absorption within about 10 minutes.

Because Roxus is currently sold as a compounded formulation without formal FDA approval, the U.S. rollout serves as an early commercial test to evaluate patient demand and adoption. Distribution through Mavrox offers a direct channel, though lack of regulatory approval and limited reimbursement could constrain scale. Meanwhile, LTR Pharma shares fell 5.38% to 0.44 AUD.

Key factors to watch include prescription volumes, customer retention rates, and safety signals. Long-term growth will depend on progress and timelines within the 505(b)(2) regulatory pathway toward full FDA approval.

## Key points

- LTR Pharma launched Roxus, an intranasal vardenafil erectile dysfunction spray, in the United States.
- The treatment is distributed as a compounded product through partner telemedicine platform Mavrox and is not FDA-approved.
- Data from prior SPONTAN studies showed median peak blood levels reached in approximately 10 minutes.
- LTR Pharma shares declined 5.38% to 0.44 AUD following the announcement.
- The company is pursuing formal FDA approval via the 505(b)(2) regulatory path.

## Questions and answers

### What is Roxus and how is it made available in the U.S.?

Roxus is a prescription intranasal vardenafil nasal spray for erectile dysfunction. It is sold in the United States as a compounded, non-FDA-approved product through the Mavrox telemedicine platform.

### Is Roxus approved by the FDA?

No, Roxus is a compounded product and is not currently approved by the FDA. However, LTR Pharma is pursuing a formal approval path through the FDA 505(b)(2) program.

### How quickly does Roxus work according to LTR Pharma?

LTR Pharma cites data from prior SPONTAN studies showing median peak blood concentrations within approximately 10 minutes.